More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down...

|About: Raptor Pharmaceutical Corp. (RPTP)|By:, SA News Editor

More on Raptor Pharmaceutical (RPTP): Q4 EPS misses estimates by a large margin, and are down 28% from the same quarter last year. R&D expenses increased nearly 50% to $9M, driven largely by higher product manufacturing costs for RP103, its treatment for cystinosis, Huntington's disease and non-alcoholic steatohepatitis, plus other supporting study expenses and employee compensation. SG&A costs also ramped up during the quarter due to marketing expenses attributed to RP103 as well.